

Enw'r Pwyllgor: Name of Sub-Committee:	Exception Report from Research & Innovation Sub-Committee
Cadeirydd y Pwyllgor: Chair of Sub-Committee:	Dr Philip Kloer, Medical Director and Deputy CEO
Cyfnod Adrodd: Reporting Period:	10 th May 2021

Materion Ansawdd, Diogelwch a Phrofiad:
Quality, Safety & Experience Matters:

The Research & Innovation Sub-Committee (R&ISC) last met on 10th May 2021. The purpose of this report is to provide the Quality, Safety and Experience Assurance Committee (QSEAC) with a summary of the key points against the agenda items.

R&D Operational Team Performance

The Sub-Committee received a report on Research and Development (R&D) operations across the University Health Board (UHB), with the following noted:

- The incidence of COVID-19 across the four acute hospital sites has reduced dramatically, which has had a corresponding impact on recruitment into urgent public health badged COVID-19 studies.
- The research delivery workforce has stabilised and is now at 75% of establishment.
- The Development Team has been supporting three researchers with grant applications totalling just over £900,000. Outcomes of these applications are expected towards the end of May 2021.

R&D Risk Register

The risk register is in the process of being updated. There are currently eight active risks for R&D on the Risk Register, with the Sub-Committee receiving assurance on the management of these risks.

Research Quality Management Group Report

The Sub-Committee received a report from the Research Quality Management Group (RQMG), with the following noted:

- Good progress continues with the department's suite of written control documents.
- There are several tasks to complete in relation to the Biobank. A proposal to set up a Hywel Dda Access Committee will be brought to the next R&I Sub-Committee meeting.
- A business case for the BioBank is also being developed.

Financial Report

The Sub-Committee received the financial report with the following noted:

- The Health and Care Research Wales (HCRW) funding for 2021/22 is yet to be confirmed, with approximately 10% still under discussion.
- The Development Team will not be funded via HCRW moving forwards. However, the team should be able to be funded via R&I funds for 2021/22, with little risk. The Development Team are a vital part of R&I in ensuring the Health Board is developing researchers and has the opportunity to apply for the funding calls. The need to safeguard the existence of the team is essential.

Written Control Document Approval

- The RQMG Annual Report was approved.

Moondance Cancer Initiative

- The Sub-Committee received a presentation from the Chief Executive Officer (CEO) of Moondance, a not-for-profit company dedicated to finding solutions to help more people in Wales survive cancer.
- Proposal of an award for time to pursue innovation.
 - 8 awards between HDdUHB and Betsi Cadwaladr University Health Board (BCUHB)
 - Up to £100k each – total £450K
- Project of 6-12 months with a focus on cancer outcomes in 4 topic areas:
 - Awareness
 - Early diagnosis
 - Single pathways
 - Value Based Health Care
- The award is to be advertised late June 2021; deadline September 2021, awarded October 2021. The application form will require Executive sign off.

TriTech

- The Sub-Committee received a presentation from the Consultant Clinical Scientist, Head of Clinical Engineering regarding TriTech.
- TriTech's approach is to systematise innovation, research and value-based care and to explore how the population can benefit from technological advances. TriTech brings together three functions to support new projects: clinical engineering, R&I, and health care, with a focus on improved outcomes. The initiative has triggered commercial interest from various companies. Progress will continue to be reported via R&I Sub-Committee meetings.
- Case Study – Dr Ffion John, Clinical Psychologist from the Chronic Pain Service, presented her innovative work to develop an app for a pain management programme for patients.

Research & Innovation Strategy Update

- A draft action plan has been developed, and work has commenced to address the actions.

University Status Review Feedback

- The tri-annual review was held with Welsh Government on 16th April 2021 and was well received. The report presented will be updated in readiness for the autumn submission.
- Formal feedback from the review is expected shortly.

University Partners

The Sub-Committee received updates from the University of Wales Trinity Saint David and Aberystwyth University. There was no update from Swansea University as the representative was not in attendance.

Items for QSEAC attention

No items were identified for escalation to QSEAC.

Risgiau: Risks (include Reference to Risk Register reference):
There are no risks for R&I on the Risk Register currently that require escalation to QSEAC
Gwella Ansawdd: Quality Improvement:
No Quality Improvement items were presented for discussion.
Argymhelliad: Recommendation:
QSEAC is requested to note the content of this exception report from the Research & Innovation Sub-Committee.
Dyddiad y Cyfarfod Pwyllgor Nesaf: Date of Next Sub- Committee Meeting:
Monday 12 th July 2021 14:00-16:30